Riding the pepTIDE — The Daily Wire on Therapeutic Peptides

An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.

Topic Sections

  • Top Shots — The most significant peptide and longevity stories ranked by overall editorial score
  • Research Signals — High-credibility scientific findings from journals, preprints, and clinical sources
  • Healing & Recovery — Tissue repair, injury recovery, and gut healing peptides including BPC-157 and TB-500
  • Growth Hormone Wire — Growth hormone secretagogues, peptide stacks, and GH axis research including Ipamorelin, CJC-1295, and MK-677
  • Metabolic & GLP-1 — Metabolic health, insulin sensitivity, and GLP-1 receptor agonist research including semaglutide and tirzepatide
  • Cognitive / Nootropic — Peptides targeting brain function, memory, neuroprotection, and cognitive enhancement
  • Skin & Cosmetic — Skin repair, anti-aging, collagen synthesis, and cosmetic peptide research including GHK-Cu and matrixyl
  • Reddit Finds — Community-sourced discussions, self-experimentation reports, and protocol threads from peptide communities
  • Contrarian Takes — Alternative viewpoints, dissenting research, and perspectives that challenge mainstream peptide narratives
  • Skeptic's Corner — Hype debunking, low-evidence alerts, and critical analysis of overstated peptide claims

Browse by Filter

  • Newest — Latest peptide and longevity stories
  • Most Credible — Highest credibility-scored stories
  • Most Edgy — High-novelty, unconventional findings
  • Most Discussed — Trending community discussions
  • Most Actionable — Direct applicability to daily health protocols
  • Lowest Risk — Stories with strong evidence, low hype
  • Research Only — Peer-reviewed and preprint studies
  • Reddit Only — Community discussion and anecdote
  • GLP-1 / Metabolic — Semaglutide, tirzepatide, and metabolic peptides
  • Healing / Recovery — BPC-157, TB-500, and repair protocols

More

  • About Riding the pepTIDE
  • Health Disclaimer
  • Submit a Source
  • Contact

Week 13 of Semaglutide: Severe Stomach Troubles — Should You Lower Dose?

Someone taking semaglutide (the drug in Ozempic/Wegovy) posted that at week 13 their refill bumped their dose to 60 units and they’ve had stomach problems and diarrhea since the shot. They’re asking whether to tough it out and hope the side effects settle, or to reduce the next dose to 30 or 45 units. This is a personal report from one person, not a formal study. Semaglutide is a medicine that copies a natural gut hormone that helps control appetite and digestion. Doctors prescribe it for type 2 diabetes and for weight loss under brand names like Ozempic and Wegovy. It works by acting on brain and gut receptors to slow stomach emptying and make you feel fuller. People usually inject it once a week, and the dose is often increased stepwise to reach a maintenance level. What we have here is anecdote — one person describing side effects after a routine dose increase. That matters because gastrointestinal symptoms (nausea, stomach pain, diarrhea, constipation) are common when starting or increasing semaglutide. For many people these side effects ease over a few days to a few weeks as the body adjusts. But the report doesn’t tell us about medical history, other meds, how long prior stomach issues lasted, or whether they contacted their prescriber. It also doesn’t say how severe the diarrhea is or whether there are signs of dehydration, which would change the urgency. Why this matters: if you’re on a semaglutide regimen or thinking about it, dose increases are the usual trigger for stomach upset. Knowing that others get symptoms after a bump to a higher dose helps set expectations: you might need a short adjustment period, or you might need to pause dose escalation. It’s useful information for patients deciding whether to call their clinician, change the dose, or prepare with dietary adjustments and fluids. Caveats and risks: this is not medical advice. You shouldn’t change dose or stop medication without talking to the prescriber. Persistent vomiting or severe diarrhea (especially with dizziness, fainting, or little urine) should prompt urgent medical attention because of dehydration or electrolyte problems. Some people can reduce the dose or stay on a lower dose longer while side effects settle, but only a clinician can advise the best plan for an individual. Also, over-the-counter remedies and abrupt changes can interact with other conditions or drugs. Bottom line: stomach issues after a dose increase are common and sometimes temporary, but don’t ignore severe or prolonged symptoms — check with your prescriber before adjusting the dose.

Source: r/Semaglutide

Read full story

Back to Riding the pepTIDE